Bicycle Therapeutics Limited Stock Price, News & Analysis

Bicycle Therapeutics presented additional human imaging data for their MT1-MMP targeting Bicycle® Radioconjugates (BRC®) at AACR 2025. The data, representing 12 patients with various solid tumors, validates MT1-MMP as a promising cancer target.

Key findings include successful imaging results from two patients:

• A 65-year-old male with advanced lung cancer showed BRC tracer uptake in primary tumor, lymph nodes, and bones
• An 84-year-old female with breast and bladder cancer demonstrated higher BRC tracer uptake in primary tumors compared to conventional imaging

The company reports positive outcomes in 12 out of 14 patients tested across various cancers. Looking ahead, Bicycle Therapeutics expects to share initial human imaging data for their second target EphA2 in late 2025, with company-sponsored radiopharmaceutical trials planned for 2026.

Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to eight new employees on April 1, 2025. The awards, approved by the Compensation Committee under the company's 2024 Inducement Plan, consist of non-qualified share options to purchase a total of 32,400 ordinary shares.

The options were granted at an exercise price of $8.49 per share, matching Bicycle's closing trading price on March 31, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting monthly over the subsequent 36 months, contingent on continued employment.

Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide (Bicycle®) technology, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, April 8, at 12:45 p.m. ET.

Investors and interested parties can access a live webcast of the presentation through the Investor section of Bicycle Therapeutics' website (www.bicycletherapeutics.com). The company will also make a replay of the webcast available for viewing after the event.

Bicycle Therapeutics (NASDAQ: BCYC) announced significant leadership changes to strengthen its oncology expertise. Felix J. Baker, Ph.D., will become chairman of the Board of Directors, succeeding Pierre Legault who will retire after the Annual General Meeting in June 2025. Alessandro Riva, M.D., joins the Board of Directors, while Fabrice André, M.D., Ph.D., joins the Clinical Advisory Board.

The company also announced internal promotions, with Eric Westin, M.D., elevated to chief medical officer and Jim MacDonald-Clink promoted to senior vice president, head of business development. These appointments follow the transitions of Santiago Arroyo and Nigel Crockett to advisor roles as distinguished fellows.

Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to eight new employees on March 3, 2025. The awards, approved by the Compensation Committee under the company's 2024 Inducement Plan, consist of non-qualified share options to purchase 73,700 ordinary shares.

The options have an exercise price of $10.97 per share, matching Bicycle's closing price on February 28, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting monthly over 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Bicycle Therapeutics (NASDAQ: BCYC) reported its Q4 and full-year 2024 financial results and recent business progress. Updated Phase 1 data for zelenectide pevedotin plus pembrolizumab in metastatic urothelial cancer showed a 65% overall response rate among 20 efficacy evaluable patients. Enhanced response was observed in NECTIN4 gene-amplified breast and lung cancers, leading to FDA Fast Track designations. Several Phase 1/2 trials are expected in 2025.

The company is advancing its radiopharmaceuticals pipeline with additional MT1-MMP human imaging data expected mid-2025 and first EphA2 human imaging data planned for 2H 2025. Cash and cash equivalents were $879.5 million as of December 31, 2024, providing financial runway into 2H 2027.

R&D expenses were $49.8 million for Q4 and $173.0 million for the year, while G&A expenses were $21.6 million for Q4 and $72.2 million for the year. Net loss was $51.9 million for Q4 and $169.0 million for the year, compared to $49.1 million and $180.7 million, respectively, in 2023.

Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide technology, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat on Wednesday, February 12, at 10 a.m. ET.

The event will be accessible through a live webcast available on the Investor section of Bicycle Therapeutics' website (www.bicycletherapeutics.com). For those unable to attend live, a replay of the webcast will be archived and made available after the event.

Bicycle Therapeutics (NASDAQ: BCYC) has announced the approval of inducement awards for 18 new employees by its Board's Compensation Committee. The awards, granted on February 3, 2025, consist of non-qualified share options to purchase a total of 117,300 ordinary shares under the company's 2024 Inducement Plan.

The options have an exercise price of $13.39 per share, matching Bicycle's closing price on January 31, 2025. These options will vest over a four-year period, with 25% vesting after one year and the remaining shares vesting monthly over the subsequent 36 months, contingent on continued employment. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment.

Bicycle Therapeutics (NASDAQ: BCYC) announced updated Phase 1 data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer (mUC). The combination showed a 65% overall response rate among efficacy-evaluable patients, with 50% confirmed responses in 20 patients. The safety profile remained consistent with previous studies, with no patient withdrawals due to treatment-related adverse events.

The company outlined its 2025 strategic priorities, including expanding zelenectide pevedotin trials across multiple Nectin-4 associated cancers, with Phase 1/2 trials planned in breast cancer, lung cancer, and multiple tumors. Additional milestones include reporting Phase 2/3 Duravelo-2 dose selection data and advancing their radiopharmaceuticals pipeline.

As of September 2024, Bicycle reported $890.9 million in cash and cash equivalents, with an expected financial runway into second half of 2027.